The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

David Rivadeneira named director of Northwell Health Cancer Institute at Huntington

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

David Rivadeneira was named director of the Northwell Health Cancer Institute at Huntington. For the past seven years, Rivadeneira has led surgical services and colorectal surgery at Huntington Hospital.

Rivadeneira specializes in laparoscopic, and other minimally invasive procedures including advanced robotic procedures for the treatment of colon and rectal diseases, including cancer. He is a professor of surgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
PodcastThe Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
By Sara Willa Ernst and Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account